SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-022901
Filing Date
2022-11-08
Accepted
2022-11-08 07:20:56
Documents
56
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q sage-20220930.htm   iXBRL 10-Q 3961103
2 EX-31.1 sage-ex31_1.htm EX-31.1 14410
3 EX-31.2 sage-ex31_2.htm EX-31.2 14390
4 EX-32.1 sage-ex32_1.htm EX-32.1 13407
5 GRAPHIC img92281125_0.jpg GRAPHIC 158107
  Complete submission text file 0000950170-22-022901.txt   12932931

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT sage-20220930_def.xml EX-101.DEF 195888
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT sage-20220930_pre.xml EX-101.PRE 308513
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT sage-20220930_cal.xml EX-101.CAL 42475
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT sage-20220930_lab.xml EX-101.LAB 404423
10 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT sage-20220930.xsd EX-101.SCH 48074
50 EXTRACTED XBRL INSTANCE DOCUMENT sage-20220930_htm.xml XML 2934231
Mailing Address 215 FIRST STREET CAMBRIDGE MA 02142
Business Address 215 FIRST STREET CAMBRIDGE MA 02142 617-299-8380
Sage Therapeutics, Inc. (Filer) CIK: 0001597553 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36544 | Film No.: 221367212
SIC: 2834 Pharmaceutical Preparations